Boosters of a therapeutic HIV-1 vaccine induce divergent T cell responses related to regulatory mechanisms

Vaccine

Volumn 31, Issue 41, 2013, Pages 4611-4618

  Lind, Andreas ^a,b   Brekke, Kristin ^a   Sommerfelt, Maja ^c   Holmberg, Jens O ^c   Aass, Hans Christian D ^a   Baksaas, Ingebjørg ^d   Sørensen, Birger ^c   Dyrhol Riise, Anne Ma ^a,b   Kvale, Dag ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c Bionor Pharma ASA   (Norway)

^d Mericon AS   (Norway)

Author keywords

HIV 1; Immune regulation; Immune therapy; Immunization; T cells

Indexed keywords

CHEMOKINE; GAMMA INTERFERON; GRANZYME B; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 10; INTERLEUKIN 10 ANTIBODY; INTERLEUKIN 13; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; TRANSFORMING GROWTH FACTOR BETA ANTIBODY;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CELLULAR IMMUNITY; CLINICAL ARTICLE; DEGRANULATION; DELAYED HYPERSENSITIVITY; ERYTHEMA; FATIGUE; FEVER; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNIZATION; IMMUNOREGULATION; MYALGIA; OPEN STUDY; PRIORITY JOURNAL; REGULATORY MECHANISM; SWELLING; T LYMPHOCYTE;

HIV-1; IMMUNE REGULATION; IMMUNE THERAPY; IMMUNIZATION; T CELLS;

AIDS VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CYTOKINES; FEMALE; GRANZYMES; HIV-1; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNIZATION, SECONDARY; IMMUNOSUPPRESSION; MALE; MIDDLE AGED;

EID: 84883599595     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.07.037     Document Type: Article

References (26)

1. Brenchley J.M., Schacker T.W., Ruff L.E., Price D.A., Taylor J.H., Beilman G.J., et al. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 2004, 200(6):749-759.
2. Rosenberg E.S., Billingsley J.M., Caliendo A.M., Boswell S.L., Sax P.E., Kalams S.A., et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 1997, 278(5342):1447-1450.
3. Pantaleo G., Soudeyns H., Demarest J.F., Vaccarezza M., Graziosi C., Paolucci S., et al. Evidence for rapid disappearance of initially expanded HIV-specific CD8+ T cell clones during primary HIV infection. Proc Natl Acad Sci USA 1997, 94(18):9848-9853.
4. Hunt P.W., Landay A.L., Sinclair E., Martinson J.A., Hatano H., Emu B., et al. A low T regulatory cell response may contribute to both viral control and generalized immune activation in HIV controllers. PLoS One 2011, 6(1):e15924.
5. Elahi S., Dinges W.L., Lejarcegui N., Laing K.J., Collier A.C., Koelle D.M., et al. Protective HIV-specific CD8+ T cells evade Treg cell suppression. Nat Med 2011, 17(8):989-995.
6. Streeck H., Jolin J.S., Qi Y., Yassine-Diab B., Johnson R.C., Kwon D.S., et al. Human immunodeficiency virus type 1-specific CD8+ T cell responses during primary infection are major determinants of the viral set point and loss of CD4+ T cells. J Virol 2009, 83(15):7641-7648.
7. Betts M.R., Nason M.C., West S.M., De Rosa S.C., Migueles S.A., Abraham J., et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 2006, 107(12):4781-4789.
8. Maggiolo F., Callegaro A., Cologni G., Bernardini C., Velenti D., Gregis G., et al. Ultrasensitive assessment of residual low-level HIV viremia in HAART-treated patients and risk of virological failure. J Acquir Immune Defic Syndr 2012, 60(5):473-482.
9. Kran A.M., Sorensen B., Nyhus J., Sommerfelt M.A., Baksaas I., Bruun J.N., et al. HLA- and dose-dependent immunogenicity of a peptide-based HIV-1 immunotherapy candidate (Vacc-4x). AIDS 2004, 18(14):1875-1883.
10. Kran A.M., Sorensen B., Sommerfelt M.A., Nyhus J., Baksaas I., Kvale D. Long-term HIV-specific responses and delayed resumption of antiretroviral therapy after peptide immunization targeting dendritic cells. AIDS 2006, 20(4):627-630.
11. Kran A.M., Sommerfelt M.A., Sorensen B., Nyhus J., Baksaas I., Bruun J.N., et al. Reduced viral burden amongst high responder patients following HIV-1 p24 peptide-based therapeutic immunization. Vaccine 2005, 23(31):4011-4015.
12. Rockstroh J, Pollard R, Pantaleo G, Podzamczer D, Asmuth J, van Lunzen J, et al. The Vacc-4x Study Group. A phase II, randomized, double-blind, multicenter, immunogenicity study of Vacc-4x versus placebo in patients infected with HIV-1 who have maintained an adequate response to ART [abstract]. AIDS2012. Washington, USA; 2012.
13. Kran A.M., Jonassen T.O., Sommerfelt M.A., Lovgarden G., Sorensen B., Kvale D. Low frequency of amino acid alterations following therapeutic immunization with HIV-1 Gag p24-like peptides. AIDS 2010, 24(17):2609-2618.
14. Lind A., Sommerfelt M., Holmberg J.O., Baksaas I., Sorensen B., Kvale D. Intradermal vaccination of HIV-infected patients with short HIV Gag p24-like peptides induces CD4+ and CD8+ T cell responses lasting more than seven years. Scand J Infect Dis 2012, 22:566-572.
15. Kaufmann D.E., Kavanagh D.G., Pereyra F., Zaunders J.J., Mackey E.W., Miura T., et al. Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction. Nat Immunol 2007, 8(11):1246-1254.
16. Moreno-Fernandez M.E., Presicce P., Chougnet C.A. Homeostasis and function of regulatory T cells in HIV/SIV infection. J Virol 2012, 86(19):10262-10269.
17. Alatrachi N., Graham C.S., van der Vliet H.J.J., Sherman K.E., Exley M.A., Koziel M.J. Hepatitis C virus (HCV)-specific CD8+ cells produce transforming growth factor b that can suppress HCV-specific T-cell responses. J Virol 2007, 81(11):5882-5892.
18. Pettersen F.O., Tasken K., Kvale D. Combined Env- and Gag-specific T cell responses in relation to programmed death-1 receptor and CD4 T cell loss rates in human immunodeficiency virus-1 infection. Clin Exp Immunol 2010, 161(2):315-323.
19. Maecker H.T., Trotter J. Flow cytometry controls, instrument setup, and the determination of positivity. Cytometry A 2006, 69(9):1037-1042.
20. Nyhus J., Kran A.M., Sommerfelt M.A., Baksaas I., Sorensen B., Kvale D. Multiple antigen concentrations in delayed-type hypersensitivity (DTH) and response diversity during and after immunization with a peptide-based HIV-1 immunotherapy candidate (Vacc-4x). Vaccine 2006, 24(10):1543-1550.
21. Holm M., Pettersen F.O., Kvale D. PD-1 predicts CD4 loss rate in chronic HIV-1 infection better than HIV RNA and CD38 but not in cryopreserved samples. Curr HIV Res 2008, 6(1):49-58.
22. Day C.L., Kaufmann D.E., Kiepiela P., Brown J.A., Moodley E.S., Reddy S., et al. PD-1 expression on HIV-specific T cells is associated with T cell exhaustion and disease progression. Nature 2006, 443(7109):350-354.
23. Kiepiela P., Ngumbela K., Thobakgale C., Ramduth D., Honeyborne I., Moodley E., et al. CD8+ T cell responses to different HIV proteins have discordant associations with viral load. Nat Med 2007, 13(1):46-53.
24. Migueles S.A., Osborne C.M., Royce C., Compton A.A., Joshi R.P., Weeks K.A., et al. Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control. Immunity 2008, 29(6):1009-1021.
25. Brooks D.G., Lee A.M., Elsaesser H., McGavern D.B., Oldstone M.B.A. IL-10 blockade facilitates DNA vaccine-induced T cell responses and enhances clearance of persistent virus infection. J Exp Med 2008, 205(3):533-541.
26. Kaufmann D.E., Walker B.D. PD-1 and CTLA-4 inhibitory cosignaling pathways in HIV infection and the potential for therapeutic intervention. J Immunol 2009, 182(10):5891-5897.